ERBB2 and breast cancer: This systematic review and meta-analysis compares the incidence of cardiotoxic effects of antibody-drug conjugates vs standard chemotherapy regimens for erb-b2 receptor tyrosine kinase 2 (ERBB2)–positive locally advanced or metastatic breast cancer (BC).